DuLac Farmaceutici, an Italian wellness company, is accelerating its push into the U.S. market with the announcement that its products are now available through OneLavi.com, just as it prepares to participate in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These two developments represent critical steps in the company's strategy to significantly expand its American footprint.
According to the company, the U.S. is a significant long-term growth market, and DuLac is not relying on a single sales channel. Instead, it is building a broader presence that combines established demand on Amazon, expanded e-commerce availability through OneLavi, and direct engagement with retailers and distribution partners at ECRM. Gabriele Bollani, Founder and CEO of DuLac Farmaceutici, emphasized the timing: "ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market. Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."
DuLac enters this next phase with a proven track record of U.S. consumer demand. On Amazon, its Arnica Gel 98% has earned more than 13,000 customer reviews with an average 4.5-star rating, while the Dinaven line has received over 4,000 reviews and maintains a 4.6-star average. The addition of OneLavi provides another platform to introduce its Made in Italy portfolio to American consumers, broadening its e-commerce reach.
The ECRM participation adds a business-to-business dimension to the expansion. During the session, DuLac will hold scheduled meetings with buyers from major health, specialty, food, drug, and mass retail channels. This offers an opportunity to present its Italian-developed products, pharmaceutical heritage, and advanced manufacturing capabilities to potential retail partners. Among the products highlighted will be the high-concentration Arnica Gel 98% range and the Dinaven and Diosmin lines. The company's objective extends beyond gaining additional points of distribution; it aims to establish relationships that support a much larger and more diversified U.S. retail presence.
DuLac brings more than 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to its U.S. expansion. Its product development and manufacturing capabilities include the proprietary Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, solvent-free Supercritical CO₂ Extraction, and manufacturing under internationally recognized GMP and ISO quality frameworks. This combination of heritage, research, and advanced production technologies provides a solid foundation for growth.
With Amazon already established, OneLavi now live, and scheduled meetings with major retail buyers planned through ECRM, DuLac is moving from initial market development toward a broader national expansion strategy. The company's goal is to build a diversified U.S. presence across e-commerce, retail, wholesale, and other distribution channels, introducing more American consumers to its brand and product portfolio.
